A highly purified guinea pig antiserum to insulin Aspart (NovoLog®) was prepared by a multi-stepped proprietary
process to yield an antiserum ideal for supporting PK analysis in animals and humans. This purified antiserum is
specific for insulin aspart and displays low reactivity with endogenous insulin and other analogs. This next generation
antiserum was generated to provide investigators with a specific antiserum for use in ELISAs to quantify insulin aspart
in the presence of endogenous and other analogs, such as insulin glargine. The antiserum is suitable for use in
ELISAs/RIAs, as an immunoaffinity capture reagent in LC-MS/MS assays and for preparation of serum QCs for use in
assays to detect and characterize ADA to glargine. The immunogen consisted of pharma-grade insulin aspart.
Suggested starting dilutions are: ELISA: 1/1,000, RIA: 1/5,000, and Immunoaffinity capture: 1/500